Literature DB >> 9684924

The biology of interferon-alpha and the clinical significance of anti-interferon antibodies.

J P Hanley1, G H Haydon.   

Abstract

The therapeutic indications for Interferons (IFNs) have dramatically increased in number in recent years to include many different diseases of viral, malignant, angiogenic, allergic, inflammatory and fibrotic origin. In particular, the current pandemic of hepatitis C virus infection has further stimulated the requirement for a comprehensive understanding of both the mechanism of action of IFN and the reasons for therapeutic failure. The role of anti-IFN antibodies as a cause of treatment failure has been a particularly controversial area. In this review we will outline the biology and proposed mechanisms of action of IFN-alpha (IFN-alpha) and discuss the incidence, methods of detection and clinical significance of anti-IFN antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684924     DOI: 10.3109/10428199809068563

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.

Authors:  Xi Chen; Lu Lu; Zhi Qi; Hong Lu; Ji Wang; Xiaoxia Yu; Yinghua Chen; Shibo Jiang
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Type I interferon production in cattle infected with 2 strains of foot-and-mouth disease virus, as determined by in situ hybridization.

Authors:  C C Brown; J Chinsangaram; M J Grubman
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

3.  Results of interferon-alfa therapy in patients with Behçet uveitis.

Authors:  Ilknur Tugal-Tutkun; Esra Güney-Tefekli; Meri Urgancioglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

4.  Relationship between response to interferon-alpha and function of peripheral blood mononuclear cells in chronic hepatitis C patients.

Authors:  Fatima Esquivel; Agustín Albillos; Flavio Carrión; Alfredo Prieto; Eduardo Reyes; Belén Martínez-Martin; José Luis Calleja; Guillermo Cacho; Melchor Alvarez-Mon
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 5.  The current status of immunobased therapies for metastatic renal-cell carcinoma.

Authors:  Niranjan J Sathianathen; Suprita Krishna; J Kyle Anderson; Christopher J Weight; Shilpa Gupta; Badrinath R Konety; Thomas S Griffith
Journal:  Immunotargets Ther       Date:  2017-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.